Monte Rosa Therapeutics, Inc. (GLUE) Cash Flow Statement
Where GLUE’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$22.8M −154.3% vs 2024
- Capital expenditures
- $4.7M 3.8% of revenue
- Free cash flow
- −$27.5M −22.2% margin
- Returned to shareholders
- $357,000
- Change in cash
- −$94.3M cash at year-end $134.8M
Drawn to scale: where the cash came from and how it was used. Hover for values.
GLUE operating cash flow, capex and free cash flow
GLUE cash flow trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$6.2M2019 | −$22.8M2025 | — | |
| Capital expenditures | $1.4M2019 | $4.7M2025 | +22.6%/yr | |
| Free cash flow | −$7.6M2019 | −$27.5M2025 | — | |
| Free cash flow margin | 50.3%2024 | −22.2%2025 | −72.5 pts | |
| Stock-based compensation | $02019 | $18.9M2025 | — | |
| Share buybacks (net) | $02019 | $357,0002025 | — | |
| Capex / revenue | 5.3%2024 | 3.8%2025 | −1.5 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
GLUE cash flow by activity
GLUE net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
GLUE cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | −$38.6M | −$72.7M | −$135.4M | −$108.5M | −$74.0M | −$35.9M | −$7.7M |
| Depreciation & amortization | $8.4M | $8.1M | $6.2M | $3.7M | $2.1M | $537,000 | $72,000 |
| Stock-based compensation | $18.9M | $18.1M | $16.7M | $11.7M | $5.2M | $354,000 | $0 |
| Change in working capital | −$9.2M | $91.4M | $72.5M | −$2.1M | $6.3M | $4.3M | $1.8M |
| Other non-cash items | −$2.2M | −$2.9M | −$3.8M | $2.8M | $977,000 | $7.7M | −$276,000 |
| Cash from operating activities | −$22.8M | $42.0M | −$43.8M | −$92.5M | −$59.4M | −$23.1M | −$6.2M |
| Investing activities | |||||||
| Capital expenditures | −$4.7M | −$4.0M | −$19.0M | −$12.9M | −$9.7M | −$3.4M | −$1.4M |
| Investments (net) | −$97.1M | −$44.5M | $20.6M | −$206.4M | −$9.7M | −$3.4M | −$1.4M |
| Acquisitions & other investing | $0 | $4.0M | $87.3M | $109,000 | $9.7M | $3.4M | $1.4M |
| Cash from investing activities | −$101.8M | −$44.5M | $88.8M | −$219.2M | −$9.7M | −$3.4M | −$1.4M |
| Financing activities | |||||||
| Share repurchases & issuance (net) | −$357,000 | −$641,000 | −$116,000 | $20.8M | $377.6M | −$440,000 | $0 |
| Net borrowing (repayment) | — | — | — | — | — | — | $9.0M |
| Shares issued | $24.2M | $944,000 | $0 | $20.1M | $380.8M | $60.5M | $14.2M |
| Other financing | $6.5M | $98.6M | $27.6M | −$20.4M | −$380.8M | $0 | −$8.2M |
| Cash from financing activities | $30.4M | $98.9M | $27.5M | $20.5M | $377.6M | $60.1M | $15.0M |
| Summary | |||||||
| Net change in cash | −$94.3M | $96.4M | $72.5M | −$291.2M | $308.5M | $32.5M | $7.4M |
| Cash at end of period | $134.8M | $229.1M | $132.7M | $60.2M | $351.4M | $41.7M | $9.2M |
| Free cash flow | −$27.5M | $38.0M | −$62.8M | −$105.4M | −$69.1M | −$26.4M | −$7.6M |
| Free cash flow margin | −22.2% | 50.3% | — | — | — | — | — |
| Capex / revenue | 3.8% | 5.3% | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$43.4M | −$44.5M | −$46.1M | −$27.1M | −$12.3M | $46.9M | $13.4M | −$23.9M | −$30.3M | −$32.0M | −$33.3M | −$34.9M |
| Depreciation & amortization | $1.9M | $2.0M | $2.1M | $2.1M | $2.1M | $2.0M | $2.1M | $2.1M | $2.1M | $1.9M | $1.8M | $1.8M |
| Stock-based compensation | $6.0M | $5.9M | $4.3M | $4.4M | $4.9M | $5.3M | $4.5M | $4.3M | $4.5M | $4.9M | $4.1M | $4.5M |
| Change in working capital | −$7.6M | $141,000 | −$3.4M | $121.5M | −$28.7M | −$98.6M | $109.7M | −$2.4M | −$2.9M | −$12.9M | $57.7M | $4.4M |
| Other non-cash items | −$975,000 | −$985,000 | $87,000 | −$466,000 | −$737,000 | −$1.1M | −$696,000 | −$1.1M | −$1.1M | −$69,000 | −$737,000 | −$497,000 |
| Cash from operating activities | −$44.1M | −$37.4M | −$43.0M | $100.4M | −$34.7M | −$45.5M | $128.9M | −$21.0M | −$27.8M | −$38.2M | $29.6M | −$24.7M |
| Investing activities | ||||||||||||
| Capital expenditures | −$4.7M | −$1.9M | −$767,000 | −$651,000 | −$1.7M | −$1.6M | −$183,000 | −$399,000 | −$2.0M | −$1.4M | −$1.7M | −$1.7M |
| Investments (net) | −$24.1M | −$259.1M | −$64.3M | $38.1M | $25.3M | −$100.2M | −$30.9M | $37.7M | −$61.2M | $9.9M | $14.3M | $35.6M |
| Acquisitions & other investing | $0 | $0 | $0 | $651,000 | $1.7M | $1.6M | $183,000 | $399,000 | $2.0M | $1.4M | $1.7M | $1.7M |
| Cash from investing activities | −$28.9M | −$261.0M | −$65.1M | $38.1M | $25.3M | −$100.2M | −$30.9M | $37.7M | −$61.2M | $9.9M | $14.3M | $35.6M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | −$357,000 | — | — | — | $0 | — | — | — | — | — |
| Shares issued | $0 | $324.3M | $24.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $3.2M | $4.0M | $5.7M | $348,000 | $365,000 | $14,000 | $608,000 | $15,000 | $98.0M | $246,000 | $25.2M | $1.1M |
| Cash from financing activities | $3.2M | $328.3M | $29.6M | $348,000 | $365,000 | $14,000 | $608,000 | $15,000 | $98.0M | $246,000 | $25.2M | $1.1M |
| Summary | ||||||||||||
| Net change in cash | −$69.8M | $30.0M | −$78.5M | $138.9M | −$9.0M | −$145.7M | $98.6M | $16.8M | $9.1M | −$28.3M | $69.0M | $12.0M |
| Cash at end of period | $95.0M | $159.9M | $134.8M | $213.3M | $74.4M | $78.5M | $229.1M | $130.5M | $108.8M | $99.8M | $128.1M | $59.1M |
| Free cash flow | −$48.8M | −$39.2M | −$43.8M | $99.8M | −$36.4M | −$47.1M | $128.7M | −$21.4M | −$29.8M | −$39.5M | $27.9M | −$26.4M |
| Free cash flow margin | −544.6% | −932.0% | −1,574.3% | 781.5% | −157.0% | −55.4% | 212.3% | −232.1% | −634.5% | −3,717.0% | 319.3% | — |
| Capex / revenue | 52.7% | 44.4% | 27.6% | 5.1% | 7.3% | 1.9% | 0.3% | 4.3% | 43.1% | 130.1% | 19.3% | — |
| Operating cash flow / net income | — | — | — | — | — | −0.97 | 9.59 | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
GLUE cash generation
In fiscal 2025 (ended December 31, 2025), Monte Rosa Therapeutics generated -$22.8 million of cash from operations (down 154.3%) and spent $4.7 million on capital expenditures, leaving free cash flow of -$27.5 million, −22.2% of revenue. It returned $0.4 million to shareholders through dividends ($0) and net share buybacks ($0.4 million). Cash and equivalents fell by $94.3 million over the year.
Related: GLUE income statement, GLUE balance sheet. See the GLUE stock overview for the latest quote and news.
GLUE cash flow FAQ
What is Monte Rosa Therapeutics's free cash flow?
Monte Rosa Therapeutics's free cash flow was -$27.5 million in fiscal 2025: -$22.8 million of operating cash flow minus $4.7 million of capital expenditures It was $38.0 million a year earlier..
How much cash does Monte Rosa Therapeutics generate from operations?
Monte Rosa Therapeutics generated -$22.8 million of cash from operating activities in fiscal 2025.
How much does Monte Rosa Therapeutics spend on capital expenditures?
Monte Rosa Therapeutics spent $4.7 million on capital expenditures in fiscal 2025, 3.8% of revenue, compared with $4.0 million the year before.
How much stock does Monte Rosa Therapeutics buy back?
Monte Rosa Therapeutics spent $0.4 million on net share repurchases in fiscal 2025.